Role of xanthine oxidoreductase in cardiac nitroso-redox imbalance

Frontiers in Bioscience

Volumn 14, Issue 1, 2009, Pages 237-262

  Tziomalos, Konstantinos ^a   Hare, Joshua M ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Clinical Research Building   (United States)

Author keywords

Heart failure; Nitric oxide; Nitroso redox imbalance; Review; S nitrosylation; Xanthine oxidoreductase

Indexed keywords

ANTIOXIDANT; REACTIVE OXYGEN METABOLITE; XANTHINE DEHYDROGENASE;

ADIPOCYTE; ANIMAL; HEART CONTRACTION; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HUMAN; METABOLISM; NITROSATION; OXIDATION REDUCTION REACTION; REVIEW;

ADIPOCYTES; ANIMALS; ANTIOXIDANTS; HUMANS; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NITROSATION; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES; XANTHINE DEHYDROGENASE;

EID: 63849201518     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3243     Document Type: Article

References (232)

1. M. Tendera: The epidemiology of heart failure. J Renin Angiotensin Aldosterone Syst 5 Suppl 1, S2-S6 (2004) (Pubitemid 39406440)
2. American Heart Association: Heart disease and stroke statistics; 2005 update. (2007)
3. F. A. Masoudi, E. P. Havranek and H. M. Krumholz: The burden of chronic congestive heart failure in older persons: magnitude and implications for policy and research. Heart Fail Rev 7, 9-16(2002) (Pubitemid 34154897)
4. S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, J. A. Oates, P. S. Rahko, M. A. Silver, L. W. Stevenson, C. W. Yancy, E. M. Antman, S. C. Smith, Jr., C. D. Adams, J. L. Anderson, D. P. Faxon, V. Fuster, J. L. Halperin, L. F. Hiratzka, A. K. Jacobs, R. Nishimura, J. P. Ornato, R. L. Page and B. Riegel: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112, e154-e235 (2005)
5. J. M. Hare and J. S. Stamler: NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest 115, 509-517(2005) (Pubitemid 40322220)
6. J. M. Zimmet and J. M. Hare: Nitroso-redox interactions in the cardiovascular system. Circulation 114, 1531-1544(2006) (Pubitemid 44527009)
7. M. Seddon, Y. H. Looi and A. M. Shah: Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart 93, 903-907(2007) (Pubitemid 47122034)
8. Z. Mallat, I. Philip, M. Lebret, D. Chatel, J. Maclouf and A. Tedgui: Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation 97, 1536-1539(1998) (Pubitemid 28186180)
9. J. J. Belch, A. B. Bridges, N. Scott and M. Chopra: Oxygen free radicals and congestive heart failure. Br Heart J 65, 245-248(1991)
10. M. Nonaka-Sarukawa, K. Yamamoto, H. Aoki, H. Takano, T. Katsuki, U. Ikeda and K. Shimada: Increased urinary 15-F2t-isoprostane concentrations in patients with non-ischaemic congestive heart failure: a marker of oxidative stress. Heart 89, 871-874(2003) (Pubitemid 36920809)
11. M. Keith, A. Geranmayegan, M. J. Sole, R. Kurian, A. Robinson, A. S. Omran and K. N. Jeejeebhoy: Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 31, 1352-1356(1998) (Pubitemid 28219127)
12. J. M. Hare: Oxidative stress and apoptosis in heart failure progression. Circ Res 89, 198-200(2001) (Pubitemid 34132678)
13. S. Kinugawa, H. Tsutsui, S. Hayashidani, T. Ide, N. Suematsu, S. Satoh, H. Utsumi and A. Takeshita: Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress. Circ Res 87, 392-398(2000)
14. K. Kameda, T. Matsunaga, N. Abe, H. Hanada, H. Ishizaka, H. Ono, M. Saitoh, K. Fukui, I. Fukuda, T. Osanai and K. Okumura: Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodelling. Eur Heart J 24, 2180-2185(2003) (Pubitemid 37522670)
15. J. T. Peterson, H. Hallak, L. Johnson, H. Li, P. M. O'Brien, D. R. Sliskovic, T. M. Bocan, M. L. Coker, T. Etoh and F. G. Spinale: Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 103, 2303-2309(2001) (Pubitemid 32433722)
16. S. Rajagopalan, X. P. Meng, S. Ramasamy, D. G. Harrison and Z. S. Galis: Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 98, 2572-2579(1996) (Pubitemid 26415078)
17. D. A. Siwik, P. J. Pagano and W. S. Colucci: Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol 280, C53-C60 (2001)
18. F. G. Spinale, M. L. Coker, S. R. Krombach, R. Mukherjee, H. Hallak, W. V. Houck, M. J. Clair, S. B. Kribbs, L. L. Johnson, J. T. Peterson and M. R. Zile: Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res 85, 364-376(1999) (Pubitemid 29398869)
19. C. V. Thomas, M. L. Coker, J. L. Zellner, J. R. Handy, A. J. Crumbley, III and F. G. Spinale: Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 97, 1708-1715(1998) (Pubitemid 28211420)
20. U. Landmesser, S. Spiekermann, S. Dikalov, H. Tatge, R. Wilke, C. Kohler, D. G. Harrison, B. Hornig and H. Drexler: Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 106, 3073-3078(2002) (Pubitemid 35440291)
21. T. P. Cappola, D. A. Kass, G. S. Nelson, R. D. Berger, G. O. Rosas, Z. A. Kobeissi, E. Marban and J. M. Hare: Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 104, 2407-2411(2001) (Pubitemid 33108372)
22. T. Ide, H. Tsutsui, S. Kinugawa, H. Utsumi, D. Kang, N. Hattori, K. Uchida, K. Arimura, K. Egashira and A. Takeshita: Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 85, 357-363(1999) (Pubitemid 29398868)
23. H. Nojiri, T. Shimizu, M. Funakoshi, O. Yamaguchi, H. Zhou, S. Kawakami, Y. Ohta, M. Sami, T. Tachibana, H. Ishikawa, H. Kurosawa, R. C. Kahn, K. Otsu and T. Shirasawa: Oxidative stress causes heart failure with impaired mitochondrial respiration. J Biol Chem 281, 33789-33801(2006) (Pubitemid 46036756)
24. F. J. Giordano: Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 115, 500-508(2005) (Pubitemid 40322219)
25. H. Mollnau, M. Oelze, M. August, M. Wendt, A. Daiber, E. Schulz, S. Baldus, A. L. Kleschyov, A. Materne, P. Wenzel, U. Hink, G. Nickenig, I. Fleming and T. Munzel: Mechanisms of increased vascular superoxide production in an experimental model of idiopathic dilated cardiomyopathy. Arterioscler Thromb Vasc Biol 25, 2554-2559(2005) (Pubitemid 43732278)
26. C. Heymes, J. K. Bendall, P. Ratajczak, A. C. Cave, J. L. Samuel, G. Hasenfuss and A. M. Shah: Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 41, 2164-2171(2003) (Pubitemid 36724261)
27. L. J. Dixon, D. R. Morgan, S. M. Hughes, L. T. McGrath, N. A. El Sherbeeny, R. D. Plumb, A. Devine, W. Leahey, G. D. Johnston and G. E. McVeigh: Functional consequences of endothelial nitric oxide synthase uncoupling in congestive cardiac failure. Circulation 107, 1725-1728(2003) (Pubitemid 36418350)
28. W. F. Saavedra, N. Paolocci, M. E. St John, M. W. Skaf, G. C. Stewart, J. S. Xie, R. W. Harrison, J. Zeichner, D. Mudrick, E. Marban, D. A. Kass and J. M. Hare: Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res 90, 297-304(2002) (Pubitemid 34633931)
29. Y. Chen, M. Hou, Y. Li, J. H. Traverse, P. Zhang, D. Salvemini, T. Fukai and R. J. Bache: Increased superoxide production causes coronary endothelial dysfunction and depressed oxygen consumption in the failing heart. Am J Physiol Heart Circ Physiol 288, H133-H141 (2005) (Pubitemid 40023840)
30. C. E. Berry and J. M. Hare: Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 555, 589-606(2004) (Pubitemid 38404582)
31. Y. Kuwabara, T. Nishino, K. Okamoto, T. Matsumura, B. T. Eger, E. F. Pai and T. Nishino: Unique amino acids cluster for switching from the dehydrogenase to oxidase form of xanthine oxidoreductase. Proc Natl Acad Sci U S A 100, 8170-8175(2003) (Pubitemid 36842517)
32. J. S. Olson, D. P. Ballou, G. Palmer and V. Massey: The mechanism of action of xanthine oxidase. J Biol Chem 249, 4363-4382(1974)
33. J. M. McCord and I. Fridovich, The reduction of cytochrome c by milk xanthine oxidase. J Biol Chem 243, 5753-5760(1968)
34. B. Halliwell and J. M. Gutteridge: Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 219, 1-14(1984) (Pubitemid 14171443)
35. T. Ide, H. Tsutsui, S. Kinugawa, N. Suematsu, S. Hayashidani, K. Ichikawa, H. Utsumi, Y. Machida, K. Egashira and A. Takeshita: Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. Circ Res 86, 152-157(2000) (Pubitemid 30086175)
36. S. Genet, R. K. Kale and N. Z. Baquer: Effects of free radicals on cytosolic creatine kinase activities and protection by antioxidant enzymes and sulfhydryl compounds. Mol Cell Biochem 210, 23-28(2000) (Pubitemid 30629065)
37. L. C. Amado, A. P. Saliaris, S. V. Raju, S. Lehrke, M. St John, J. Xie, G. Stewart, T. Fitton, K. M. Minhas, J. Brawn and J. M. Hare: Xanthine oxidase inhibition ameliorates cardiovascular dysfunction in dogs with pacing-induced heart failure. J Mol Cell Cardiol 39, 531-536(2005) (Pubitemid 41133738)
38. U. E. Ekelund, R. W. Harrison, O. Shokek, R. N. Thakkar, R. S. Tunin, H. Senzaki, D. A. Kass, E. Marban and J. M. Hare: Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res 85, 437-445(1999) (Pubitemid 29409620)
39. L. B. Stull, M. K. Leppo, L. Szweda, W. D. Gao and E. Marban: Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ Res 95, 1005-1011(2004) (Pubitemid 39534412)
40. E. Yamamoto, K. Kataoka, T. Yamashita, Y. Tokutomi, Y. F. Dong, S. Matsuba, H. Ogawa and S. Kim-Mitsuyama: Role of xanthine oxidoreductase in the reversal of diastolic heart failure by candesartan in the salt-sensitive hypertensive rat. Hypertension 50, 657-662(2007) (Pubitemid 47442728)
41. R. W. Schrier and W. T. Abraham: Hormones and hemodynamics in heart failure. N Engl J Med 341, 577-585(1999) (Pubitemid 29384167)
42. E. M. Mervaala, Z. J. Cheng, I. Tikkanen, R. Lapatto, K. Nurminen, H. Vapaatalo, D. N. Muller, A. Fiebeler, U. Ganten, D. Ganten and F. C. Luft: Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes. Hypertension 37, 414-418(2001) (Pubitemid 32199003)
43. P. Aukrust, T. Ueland, F. Muller, A. K. Andreassen, I. Nordoy, H. Aas, J. Kjekshus, S. Simonsen, S. S. Froland and L. Gullestad: Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 97, 1136-1143(1998) (Pubitemid 28152886)
44. G. Torre-Amione, S. Kapadia, C. Benedict, H. Oral, J. B. Young and D. L. Mann: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27, 1201-1206(1996) (Pubitemid 26117714)
45. P. Ferdinandy, H. Danial, I. Ambrus, R. A. Rothery and R. Schulz: Peroxynitrite is a major contributor to cytokineinduced myocardial contractile failure. Circ Res 87, 241-247(2000) (Pubitemid 30626433)
46. K. C. Flanders, A. R. Bhandiwad and T. S. Winokur: Transforming growth factor-betas block cytokine induction of catalase and xanthine oxidase mRNA levels in cultured rat cardiac cells. J Mol Cell Cardiol 29, 273-280(1997) (Pubitemid 27129151)
47. P. M. Hassoun, F. S. Yu, A. L. Shedd, J. J. Zulueta, V. J. Thannickal, J. J. Lanzillo and B. L. Fanburg: Regulation of endothelial cell xanthine dehydrogenase xanthine oxidase gene expression by oxygen tension. Am J Physiol 266, L163-L171 (1994) (Pubitemid 24100859)
48. W. B. Poss, T. P. Huecksteadt, P. C. Panus, B. A. Freeman and J. R. Hoidal: Regulation of xanthine dehydrogenase and xanthine oxidase activity by hypoxia. Am J Physiol 270, L941-L946 (1996)
49. Y. Hoshikawa, S. Ono, S. Suzuki, T. Tanita, M. Chida, C. Song, M. Noda, T. Tabata, N. F. Voelkel and S. Fujimura: Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol 90, 1299-1306(2001) (Pubitemid 32220912)
50. N. G. MacFarlane and D. J. Miller: Depression of peak force without altering calcium sensitivity by the superoxide anion in chemically skinned cardiac muscle of rat. Circ Res 70, 1217-1224(1992)
51. N. G. Perez, W. D. Gao and E. Marban: Novel myofilament Ca2+-sensitizing property of xanthine oxidase inhibitors. Circ Res 83, 423-430(1998) (Pubitemid 28389972)
52. S. A. Khan, K. Lee, K. M. Minhas, D. R. Gonzalez, S. V. Raju, A. D. Tejani, D. Li, D. E. Berkowitz and J. M. Hare: Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitationcontraction coupling. Proc Natl Acad Sci U S A 101, 15944-15948(2004) (Pubitemid 39507906)
53. W. D. Gao, Y. Liu and E. Marban: Selective effects of oxygen free radicals on excitation-contraction coupling in ventricular muscle. Implications for the mechanism of stunned myocardium. Circulation 94, 2597-2604(1996) (Pubitemid 26403591)
54. C. Ventura, C. Guarnieri and C. M. Caldarera: Inhibitory effect of superoxide radicals on cardiac myofibrillar ATPase activity. Ital J Biochem 34, 267-274(1985) (Pubitemid 16233673)
55. H. Kogler, H. Fraser, S. McCune, R. Altschuld and E. Marban: Disproportionate enhancement of myocardial contractility by the xanthine oxidase inhibitor oxypurinol in failing rat myocardium. Cardiovasc Res 59, 582-592(2003) (Pubitemid 38368674)
56. N. G. Perez, K. Hashimoto, S. McCune, R. A. Altschuld and E. Marban: Origin of contractile dysfunction in heart failure: calcium cycling versus myofilaments. Circulation 99, 1077-1083(1999) (Pubitemid 29104499)
57. H. Ishida, C. Genka, Y. Hirota, Y. Hamasaki and H. Nakazawa: Distinct roles of peroxynitrite and hydroxyl radical in triggering stunned myocardium-like impairment of cardiac myocytes in vitro. Mol Cell Biochem 198, 31-38(1999) (Pubitemid 29414519)
58. T. Ukai, C. P. Cheng, H. Tachibana, A. Igawa, Z. S. Zhang, H. J. Cheng and W. C. Little: Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing-induced heart failure. Circulation 103, 750-755(2001) (Pubitemid 32144206)
59. K. M. Minhas, R. M. Saraiva, K. H. Schuleri, S. Lehrke, M. Zheng, A. P. Saliaris, C. E. Berry, L. A. Barouch, K. M. Vandegaer, D. Li and J. M. Hare: Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circ Res 98, 271-279(2006)
60. A. V. Naumova, V. P. Chacko, R. Ouwerkerk, L. Stull, E. Marban and R. G. Weiss: Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts. Am J Physiol Heart Circ Physiol 290, H837-H843 (2006)
61. J. S. Ingwall and R. G. Weiss: Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res 95, 135-145(2004) (Pubitemid 38988679)
62. M. Beer, T. Seyfarth, J. Sandstede, W. Landschutz, C. Lipke, H. Kostler, M. von Kienlin, K. Harre, D. Hahn and S. Neubauer: Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31) P-SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol 40, 1267-1274(2002)
63. M. A. Conway, J. Allis, R. Ouwerkerk, T. Niioka, B. Rajagopalan and G. K. Radda: Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy. Lancet 338, 973-976(1991)
64. S. Neubauer, M. Horn, M. Cramer, K. Harre, J. B. Newell, W. Peters, T. Pabst, G. Ertl, D. Hahn, J. S. Ingwall and K. Kochsiek: Myocardial phosphocreatineto-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96, 2190-2196(1997) (Pubitemid 27425822)
65. W. Shen, M. Spindler, M. A. Higgins, N. Jin, R. M. Gill, L. J. Bloem, T. P. Ryan and J. S. Ingwall: The fall in creatine levels and creatine kinase isozyme changes in the failing heart are reversible: complex posttranscriptional regulation of the components of the CK system. J Mol Cell Cardiol 39, 537-544(2005) (Pubitemid 41133739)
66. L. Nascimben, J. S. Ingwall, P. Pauletto, J. Friedrich, J. K. Gwathmey, V. Saks, A. C. Pessina and P. D. Allen: Creatine kinase system in failing and nonfailing human myocardium. Circulation 94, 1894-1901(1996) (Pubitemid 26349302)
67. R. Tian and J. S. Ingwall: Energetic basis for reduced contractile reserve in isolated rat hearts. Am J Physiol 270, H1207-H1216 (1996)
68. B. L. Hamman, J. A. Bittl, W. E. Jacobus, P. D. Allen, R. S. Spencer, R. Tian and J. S. Ingwall: Inhibition of the creatine kinase reaction decreases the contractile reserve of isolated rat hearts. Am J Physiol 269, H1030-H1036 (1995)
69. H. Ishihara, M. Yokota, T. Sobue and H. Saito: Relation between ventriculoarterial coupling and myocardial energetics in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 23, 406-416(1994) (Pubitemid 24049373)
70. M. Packer, J. R. Carver, R. J. Rodeheffer, R. J. Ivanhoe, R. Di Bianco, S. M. Zeldis, G. H. Hendrix, W. J. Bommer, U. Elkayam, M. L. Kukin and G. I. Mallis, J. A. Sollano, J. Shannon, P. K. Tandon and D. L. De Mets: Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325, 1468-1475(1991)
71. C. M. O'Connor, W. A. Gattis, B. F. Uretsky, K. F. Adams, Jr., S. E. McNulty, S. H. Grossman, W. J. McKenna, F. Zannad, K. Swedberg, M. Gheorghiade and R. M. Califf: Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 138, 78-86(1999) (Pubitemid 29331125)
72. F. Del Monte and R. J. Hajjar: Targeting calcium cycling proteins in heart failure through gene transfer. J Physiol 546, 49-61(2003)
73. S. O. Marx, S. Reiken, Y. Hisamatsu, T. Jayaraman, D. Burkhoff, N. Rosemblit and A. R. Marks: PKA phosphorylation dissociates FKBP12.6. from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101, 365-376(2000)
74. R. Studer, H. Reinecke, J. Bilger, T. Eschenhagen, M. Bohm, G. Hasenfuss, H. Just, J. Holtz and H. Drexler: Gene expression of the cardiac Na (+)-Ca2+ exchanger in end-stage human heart failure. Circ Res 75, 443-453(1994)
75. U. Schmidt, R. J. Hajjar, P. A. Helm, C. S. Kim, A. A. Doye and J. K. Gwathmey: Contribution of abnormal sarcoplasmic reticulum ATPase activity to systolic and diastolic dysfunction in human heart failure. J Mol Cell Cardiol 30, 1929-1937(1998) (Pubitemid 28495319)
76. B. O'Rourke, D. A. Kass, G. F. Tomaselli, S. Kaab, R. Tunin and E. Marban: Mechanisms of altered excitationcontraction coupling in canine tachycardia-induced heart failure, I: experimental studies. Circ Res 84, 562-570(1999) (Pubitemid 29138593)
77. A. P. Saliaris, L. C. Amado, K. M. Minhas, K. H. Schuleri, S. Lehrke, M. St John, T. Fitton, C. Barreiro, C. Berry, M. Zheng, K. Kozielski, V. Eneboe, J. Brawn and J. M. Hare: Chronic allopurinol administration ameliorates maladaptive alterations in Ca2+ cycling proteins and beta-adrenergic hyporesponsiveness in heart failure. Am J Physiol Heart Circ Physiol 292, H1328-H1335 (2007) (Pubitemid 46377120)
78. I. E. Blasig, T. Grune, K. Schonheit, E. Rohde, M. Jakstadt, R. F. Haseloff and W. G. Siems: 4-Hydroxynonenal, a novel indicator of lipid peroxidation for reperfusion injury of the myocardium. Am J Physiol 269, H14-H22 (1995)
79. P. Eaton, D. J. Hearse and M. J. Shattock: Lipid hydroperoxide modification of proteins during myocardial ischaemia. Cardiovasc Res 51, 294-303(2001) (Pubitemid 32695540)
80. J. G. Duncan, R. Ravi, L. B. Stull and A. M. Murphy: Chronic xanthine oxidase inhibition prevents myofibrillar protein oxidation and preserves cardiac function in a transgenic mouse model of cardiomyopathy. Am J Physiol Heart Circ Physiol 289, H1512-H1518 (2005) (Pubitemid 41368993)
81. M. Jessup and S. Brozena: Heart failure. N Engl J Med 348, 2007-2018(2003)
82. N. Engberding, S. Spiekermann, A. Schaefer, A. Heineke, A. Wiencke, M. Muller, M. Fuchs, D. Hilfiker-Kleiner, B. Hornig, H. Drexler and U. Landmesser: Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation 110, 2175-2179(2004) (Pubitemid 39372497)
83. V. Mellin, M. Isabelle, A. Oudot, C. Vergely-Vandriesse, C. Monteil, B. Di Meglio, J. P. Henry, B. Dautreaux, L. Rochette, C. Thuillez and P. Mulder: Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure. Eur Heart J 26, 1544-1550(2005) (Pubitemid 41373497)
84. V. P. van Empel and L. J. De Windt: Myocyte hypertrophy and apoptosis: a balancing act. Cardiovasc Res 63, 487-499(2004) (Pubitemid 38970193)
85. D. Levy, R. J. Garrison, D. D. Savage, W. B. Kannel and W. P. Castelli: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322, 1561-1566(1990) (Pubitemid 20176696)
86. J. Heineke and J. D. Molkentin: Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7, 589-600(2006) (Pubitemid 44325350)
87. O. F. Bueno, L. J. De Windt, K. M. Tymitz, S. A. Witt, T. R. Kimball, R. Klevitsky, T. E. Hewett, S. P. Jones, D. J. Lefer, C. F. Peng, R. N. Kitsis and J. D. Molkentin: The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 19, 6341-6350(2000)
88. S. M. Kang, S. Lim, H. Song, W. Chang, S. Lee, S. M. Bae, J. H. Chung, H. Lee, H. G. Kim, D. H. Yoon, T. W. Kim, Y. Jang, J. M. Sung, N. S. Chung and K. C. Hwang: Allopurinol modulates reactive oxygen species generation and Ca2+ overload in ischemia-reperfused heart and hypoxia-reoxygenated cardiomyocytes. Eur J Pharmacol 535, 212-219(2006)
89. G. W. Dorn, J. Robbins and P. H. Sugden: Phenotyping hypertrophy: eschew obfuscation. Circ Res 92, 1171-1175(2003) (Pubitemid 36723642)
90. D. Cesselli, I. Jakoniuk, L. Barlucchi, A. P. Beltrami, T. H. Hintze, B. Nadal-Ginard, J. Kajstura, A. Leri and P. Anversa: Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res 89, 279-286(2001) (Pubitemid 34132687)
91. J. Narula, N. Haider, R. Virmani, T. G. Di Salvo, F. D. Kolodgie, R. J. Hajjar, U. Schmidt, M. J. Semigran, G. W. Dec. and B. A. Khaw: Apoptosis in myocytes in end-stage heart failure. N Engl J Med 335, 1182-1189(1996) (Pubitemid 26339772)
92. G. Olivetti, R. Abbi, F. Quaini, J. Kajstura, W. Cheng, J. A. Nitahara, E. Quaini, C. Di Loreto, C. A. Beltrami, S. Krajewski, J. C. Reed and P. Anversa: Apoptosis in the failing human heart. N Engl J Med 336, 1131-1141(1997)
93. H. Nagai, T. Noguchi, K. Takeda and H. Ichijo: Pathophysiological roles of ASK1-MAP kinase signaling pathways. J Biochem Mol Biol 40, 1-6(2007) (Pubitemid 46182728)
94. O. Yamaguchi, Y. Higuchi, S. Hirotani, K. Kashiwase, H. Nakayama, S. Hikoso, T. Takeda, T. Watanabe, M. Asahi, M. Taniike, Y. Matsumura, I. Tsujimoto, K. Hongo, Y. Kusakari, S. Kurihara, K. Nishida, H. Ichijo, M. Hori and K. Otsu: Targeted deletion of apoptosis signalregulating kinase 1 attenuates left ventricular remodeling. Proc Natl Acad Sci U S A 100, 15883-15888(2003) (Pubitemid 38021084)
95. K. Tobiume, A. Matsuzawa, T. Takahashi, H. Nishitoh, K. Morita, K. Takeda, O. Minowa, K. Miyazono, T. Noda and H. Ichijo: ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep 2, 222-228(2001) (Pubitemid 32273301)
96. R. A. Kaiser, Q. Liang, O. Bueno, Y. Huang, T. Lackey, R. Klevitsky, T. E. Hewett and J. D. Molkentin: Genetic inhibition or activation of JNK1/2 protects the myocardium from ischemia-reperfusion-induced cell death in vivo. J Biol Chem 280, 32602-32608(2005) (Pubitemid 41368302)
97. J. M. Adams and S. Cory: Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 26, 61-66(2001) (Pubitemid 32124712)
98. K. M. Regula and L. A. Kirshenbaum: Apoptosis of ventricular myocytes: a means to an end. J Mol Cell Cardiol 38, 3-13(2005) (Pubitemid 40038648)
99. S. Dhingra, A. K. Sharma, D. K. Singla and P. K. Singal: p38 and ERK 1/2 MAPkinases mediate interplay of TNF-and IL-10 in regulating oxidative stress and cardiac myocyte apoptosis. Am J Physiol Heart Circ Physiol 293, H3524-3531 (2007) (Pubitemid 350230896)
100. D. A. Siwik, J. D. Tzortzis, D. R. Pimental, D. L. Chang, P. J. Pagano, K. Singh, D. B. Sawyer and W. S. Colucci: Inhibition of copper-zinc superoxide dismutase induces cell growth, hypertrophic phenotype, and apoptosis in neonatal rat cardiac myocytes in vitro. Circ Res 85, 147-153(1999) (Pubitemid 29343313)
101. M. Saitoh, H. Nishitoh, M. Fujii, K. Takeda, K. Tobiume, Y. Sawada, M. Kawabata, K. Miyazono and H. Ichijo, Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17, 2596-2606(1998) (Pubitemid 28221195)
102. G. L. Gallagher, C. J. Jackson and S. N. Hunyor: Myocardial extracellular matrix remodeling in ischemic heart failure. Front Biosci 12, 1410-1419(2007) (Pubitemid 46846843)
103. A. M. Deschamps and F. G. Spinale: Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res 69, 666-676(2006) (Pubitemid 43139729)
104. F. G. Spinale: Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 90, 520-530(2002) (Pubitemid 34640901)
105. P. Sivakumar, S. Gupta, S. Sarkar and S. Sen: Upregulation of lysyl oxidase and MMPs during cardiac remodeling in human dilated cardiomyopathy. Mol Cell Biochem 307, 159-167(2008) (Pubitemid 350238658)
106. Y. Y. Li, A. M. Feldman, Y. Sun and C. F. McTiernan: Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 98, 1728-1734(1998) (Pubitemid 28492492)
107. A. Ducharme, S. Frantz, M. Aikawa, E. Rabkin, M. Lindsey, L. E. Rohde, F. J. Schoen, R. A. Kelly, Z. Werb, P. Libby and R. T. Lee: Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 106, 55-62(2000) (Pubitemid 30437240)
108. M. R. Bergman, J. R. Teerlink, R. Mahimkar, L. Li, B. Q. Zhu, A. Nguyen, S. Dahi, J. S. Karliner and D. H. Lovett: Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol 292, H1847-H1860 (2007) (Pubitemid 46572408)
109. T. Fujiwara, T. Matsunaga, K. Kameda, N. Abe, H. Ono, T. Higuma, J. Yokoyama, H. Hanada, T. Osanai and K. Okumura: Nicorandil suppresses the increases in plasma level of matrix metalloproteinase activity and attenuates left ventricular remodeling in patients with acute myocardial infarction. Heart Vessels 22, 303-309(2007) (Pubitemid 47456660)
110. M. Gheorghiade and R. O. Bonow: Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 97, 282-289(1998) (Pubitemid 28067315)
111. R. J. Hajjar, U. Schmidt, P. Helm and J. K. Gwathmey: Ca++ sensitizers impair cardiac relaxation in failing human myocardium. J Pharmacol Exp Ther 280, 247-254(1997) (Pubitemid 27171409)
112. C. E. Murdoch, M. Zhang, A. C. Cave and A. M. Shah: NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res 71, 208-215(2006)
113. C. Maack, T. Kartes, H. Kilter, H. J. Schafers, G. Nickenig, M. Bohm and U. Laufs: Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 108, 1567-1574(2003) (Pubitemid 37187782)
114. C. Nediani, E. Borchi, C. Giordano, S. Baruzzo, V. Ponziani, M. Sebastiani, P. Nassi, A. Mugelli, G. d'Amati and E. Cerbai: NADPH oxidase-dependent redox signaling in human heart failure: relationship between the left and right ventricle. J Mol Cell Cardiol 42, 826-834(2007) (Pubitemid 46527598)
115. F. Qin, M. Simeone and R. Patel: Inhibition of NADPH oxidase reduces myocardial oxidative stress and apoptosis and improves cardiac function in heart failure after myocardial infarction. Free Radic Biol Med 43, 271-281(2007) (Pubitemid 46977168)
116. J. S. McNally, M. E. Davis, D. P. Giddens, A. Saha, J. Hwang, S. Dikalov, H. Jo and D. G. Harrison: Role of xanthine oxidoreductase and NAD (P) H oxidase in endothelial superoxide production in response to oscillatory shear stress. Am J Physiol Heart Circ Physiol 285, H2290-H2297 (2003) (Pubitemid 37443044)
117. Z. Makazan, H. K. Saini and N. S. Dhalla: Role of oxidative stress in alterations of mitochondrial function in ischemic-reperfused hearts. Am J Physiol Heart Circ Physiol 292, H1986-H1994 (2007) (Pubitemid 46572425)
118. F. M. Faraci and S. P. Didion: Vascular protection: superoxide dismutase isoforms in the vessel wall. Arterioscler Thromb Vasc Biol 24, 1367-1373(2004) (Pubitemid 39050427)
119. L. Valenti, D. Conte, A. Piperno, P. Dongiovanni, A. L. Fracanzani, M. Fraquelli, A. Vergani, C. Gianni, L. Carmagnola and S. Fargion: The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary haemochromatosis. J Med Genet 41, 946-950(2004) (Pubitemid 40007257)
120. R. F. Furchgott and J. V. Zawadzki: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288, 373-376(1980) (Pubitemid 11169009)
121. F. Murad: Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med 355, 2003-2011(2006) (Pubitemid 44708019)
122. J. M. Hare: Spatial confinement of isoforms of cardiac nitric-oxide synthase: unravelling the complexities of nitric oxide's cardiobiology. Lancet 363, 1338-1339(2004) (Pubitemid 38529869)
123. K. Y. Xu, D. L. Huso, T. M. Dawson, D. S. Bredt and L. C. Becker: Nitric oxide synthase in cardiac sarcoplasmic reticulum. Proc Natl Acad Sci U S A 96, 657-662(1999) (Pubitemid 29061264)
124. O. Feron, L. Belhassen, L. Kobzik, T. W. Smith, R. A. Kelly and T. Michel: Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Biol Chem 271, 22810-22814(1996) (Pubitemid 26304729)
125. A. J. Kanai, L. L. Pearce, P. R. Clemens, L. A. Birder, M. M. Van Bibber, S. Y. Choi, W. C. de Groat and J. Peterson: Identification of a neuronal nitric oxide synthase in isolated cardiac mitochondria using electrochemical detection. Proc Natl Acad Sci U S A 98, 14126-14131(2001) (Pubitemid 33116035)
126. T. Damy, P. Ratajczak, A. M. Shah, E. Camors, I. Marty, G. Hasenfuss, F. Marotte, J. L. Samuel and C. Heymes: Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet 363, 1365-1367(2004) (Pubitemid 38529877)
127. R. M. Saraiva and J. M. Hare: Nitric oxide signaling in the
128. J. M. Hare: Nitric oxide and excitation-contraction coupling. J Mol Cell Cardiol 35, 719-729(2003) (Pubitemid 36773583)
129. L. Xu, J. P. Eu, G. Meissner and J. S. Stamler: Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. Science 279, 234-237(1998) (Pubitemid 28103882)
130. J. P. Eu, J. Sun, L. Xu, J. S. Stamler and G. Meissner: The skeletal muscle calcium release channel: coupled O2 sensor and NO signaling functions. Cell 102, 499-509(2000)
131. D. L. Campbell, J. S. Stamler and H. C. Strauss: Redox modulation of L-type calcium channels in ferret ventricular myocytes. Dual mechanism regulation by nitric oxide and S-nitrosothiols. J Gen Physiol 108, 277-293(1996) (Pubitemid 26332539)
132. J. Sun, E. Picht, K. S. Ginsburg, D. M. Bers, C. Steenbergen and E. Murphy: Hypercontractile female hearts exhibit increased S-nitrosylation of the L-type Ca2+ channel alpha1 subunit and reduced ischemia/reperfusion injury. Circ Res 98, 403-411(2006)
133. L. A. Barouch, T. P. Cappola, R. W. Harrison, J. K. Crone, E. R. Rodriguez, A. L. Burnett and J. M. Hare: Combined loss of neuronal and endothelial nitric oxide synthase causes premature mortality and age-related hypertrophic cardiac remodeling in mice. J Mol Cell Cardiol 35, 637-644(2003) (Pubitemid 36677447)
134. T. P. Cappola, L. Cope, A. Cernetich, L. A. Barouch, K. Minhas, R. A. Irizarry, G. Parmigiani, S. Durrani, T. Lavoie, E. P. Hoffman, S. Q. Ye, J. G. Garcia and J. M. Hare: Deficiency of different nitric oxide synthase isoforms activates divergent transcriptional programs in cardiac hypertrophy. Physiol Genomics 14, 25-34(2003) (Pubitemid 37345212)
135. S. J. Kim, J. W. Ju, C. D. Oh, Y. M. Yoon, W. K. Song, J. H. Kim, Y. J. Yoo, O. S. Bang, S. S. Kang and J. S. Chun: ERK-1/2 and p38 kinase oppositely regulate nitric oxide-induced apoptosis of chondrocytes in association with p53, caspase-3, and differentiation status. J Biol Chem 277, 1332-1339(2002) (Pubitemid 34968887)
136. H. M. Lander, A. T. Jacovina, R. J. Davis and J. M. Tauras: Differential activation of mitogen-activated protein kinases by nitric oxide-related species. J Biol Chem 271, 19705-19709(1996) (Pubitemid 26281705)
137. H. M. Lander, D. P. Hajjar, B. L. Hempstead, U. A. Mirza, B. T. Chait, S. Campbell and L. A. Quilliam: A molecular redox switch on p21 (ras) Structural basis for the nitric oxide-p21 (ras) interaction. J Biol Chem 272, 4323-4326(1997) (Pubitemid 27078505)
138. J. Hood and H. J. Granger: Protein kinase G mediates vascular endothelial growth factor-induced Raf-1 activation and proliferation in human endothelial cells. J Biol Chem 273, 23504-23508(1998) (Pubitemid 28417542)
139. A. Parenti, L. Morbidelli, X. L. Cui, J. G. Douglas, J. D. Hood, H. J. Granger, F. Ledda and M. Ziche: Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase1/2 activation in postcapillary endothelium. J Biol Chem 273, 4220-4226(1998) (Pubitemid 28103293)
140. C. D. Jun, C. D. Oh, H. J. Kwak, H. O. Pae, J. C. Yoo, B. M. Choi, J. S. Chun, R. K. Park and H. T. Chung: Overexpression of protein kinase C isoforms protects RAW 264.7. macrophages from nitric oxideinduced apoptosis: involvement of c-Jun. N-terminal kinase/stress-activated protein kinase, p38 kinase, and CPP-32 protease pathways. J Immunol 162, 3395-3401(1999)
141. K. W. Raines, G. L. Cao, E. K. Lee, G. M. Rosen and P. Shapiro: Neuronal nitric oxide synthase-induced S-nitrosylation of H-Ras inhibits calcium ionophoremediated extracellular-signal-regulated kinase activity. Biochem J 397, 329-336(2006) (Pubitemid 44076903)
142. J. D. Molkentin, J. R. Lu, C. L. Antos, B. Markham, J. Richardson, J. Robbins, S. R. Grant and E. N. Olson: A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93, 215-228(1998) (Pubitemid 28180855)
143. S. J. Li and N. L. Sun: Regulation of intracellular Ca2+ and calcineurin by NO/PKG in proliferation of vascular smooth muscle cells. Acta Pharmacol Sin 26, 323-328(2005)
144. B. Fiedler, S. M. Lohmann, A. Smolenski, S. Linnemuller, B. Pieske, F. Schroder, J. D. Molkentin, H. Drexler and K. C. Wollert: Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci U S A 99, 11363-11368(2002) (Pubitemid 34920931)
145. S. V. Raju, L. A. Barouch and J. M. Hare: Nitric oxide and oxidative stress in cardiovascular aging. Sci Aging Knowledge Environ 2005, re4 (2005)
146. H. S. Park, J. W. Yu, J. H. Cho, M. S. Kim, S. H. Huh, K. Ryoo and E. J. Choi: Inhibition of apoptosis signalregulating kinase 1 by nitric oxide through a thiol redox mechanism. J Biol Chem 279, 7584-7590(2004) (Pubitemid 38294637)
147. T. Yamashita, E. Yamamoto, K. Kataoka, T. Nakamura, S. Matsuba, Y. Tokutomi, Y. F. Dong, H. Ichijo, H. Ogawa and S. Kim-Mitsuyama: Apoptosis signal-regulating kinase-1 is involved in vascular endothelial and cardiac remodeling caused by nitric oxide deficiency. Hypertension 50, 519-524(2007) (Pubitemid 47312238)
148. S. Ghatan, S. Larner, Y. Kinoshita, M. Hetman, L. Patel, Z. Xia, R. J. Youle and R. S. Morrison: p38 MAP kinase mediates bax translocation in nitric oxide-induced apoptosis in neurons. J Cell Biol 150, 335-347(2000) (Pubitemid 30491357)
149. D. D. Browning, M. P. McShane, C. Marty and R. D. Ye: Nitric oxide activation of p38 mitogen-activated protein kinase in 293T fibroblasts requires cGMP-dependent protein kinase. J Biol Chem 275, 2811-2816(2000) (Pubitemid 30082053)
150. O. J. Han, K. H. Joe, S. W. Kim, H. S. Lee, N. S. Kwon, K. J. Baek and H. Y. Yun: Involvement of p38 mitogen-activated protein kinase and apoptosis signalregulating kinase-1 in nitric oxide-induced cell death in PC12 cells. Neurochem Res 26, 525-532(2001) (Pubitemid 32744304)
151. H. S. Park, S. H. Huh, M. S. Kim, S. H. Lee and E. J. Choi: Nitric oxide negatively regulates c-Jun. N-terminal kinase/stress-activated protein kinase by means of S-nitrosylation. Proc Natl Acad Sci U S A 97, 14382-14387(2000) (Pubitemid 32016584)
152. D. S. Park, L. Stefanis, C. Y. Yan, S. E. Farinelli and L. A. Greene: Ordering the cell death pathway. Differential effects of BCL2, an interleukin-1-converting enzyme family protease inhibitor, and other survival agents on JNK activation in serum/nerve growth factor-deprived PC12 cells. J Biol Chem 271, 21898-21905(1996) (Pubitemid 26303812)
153. H. S. So, R. K. Park, M. S. Kim, S. R. Lee, B. H. Jung, S. Y. Chung, C. D. Jun. and H. T. Chung: Nitric oxide inhibits c-Jun. N-terminal kinase 2 (JNK2) via S-nitrosylation. Biochem Biophys Res Commun 247, 809-813(1998) (Pubitemid 28418473)
154. M. Trujillo, M. N. Alvarez, G. Peluffo, B. A. Freeman and R. Radi: Xanthine oxidase-mediated decomposition of S-nitrosothiols. J Biol Chem 273, 7828-7834(1998) (Pubitemid 28168826)
155. H. Li, A. Samouilov, X. Liu and J. L. Zweier: Characterization of the magnitude and kinetics of xanthine oxidase-catalyzed nitrite reduction. Evaluation of its role in nitric oxide generation in anoxic tissues. J Biol Chem 276, 24482-24489(2001)
156. K. Ichimori, M. Fukahori, H. Nakazawa, K. Okamoto and T. Nishino: Inhibition of xanthine oxidase and xanthine dehydrogenase by nitric oxide. Nitric oxide converts reduced xanthine-oxidizing enzymes into the desulfo-type inactive form. J Biol Chem 274, 7763-7768(1999)
157. P. M. Hassoun, F. S. Yu, J. J. Zulueta, A. C. White and J. J. Lanzillo: Effect of nitric oxide and cell redox status on the regulation of endothelial cell xanthine dehydrogenase. Am J Physiol 268, L809-L817 (1995)
158. S. Kinugawa, H. Huang, Z. Wang, P. M. Kaminski, M. S. Wolin and T. H. Hintze: A defect of neuronal nitric oxide synthase increases xanthine oxidase-derived superoxide anion and attenuates the control of myocardial oxygen consumption by nitric oxide derived from endothelial nitric oxide synthase. Circ Res 96, 355-362(2005) (Pubitemid 40279910)
159. R. M. Saraiva, K. M. Minhas, S. V. Raju, L. A. Barouch, E. Pitz, K. H. Schuleri, K. Vandegaer, D. Li and J. M. Hare: Deficiency of neuronal nitric oxide synthase increases mortality and cardiac remodeling after myocardial infarction: role of nitroso-redox equilibrium. Circulation 112, 3415-3422(2005) (Pubitemid 43739556)
160. R. S. Smith, Jr., J. Agata, C. F. Xia, L. Chao and J. Chao: Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction. Life Sci 76, 2457-2471(2005) (Pubitemid 40341962)
161. L. Kalinowski and T. Malinski: Endothelial NADH/NADPH-dependent enzymatic sources of superoxide production: relationship to endothelial dysfunction. Acta Biochim Pol 51, 459-469(2004) (Pubitemid 38969307)
162. J. M. Hare: Nitroso-redox balance in the cardiovascular system. N Engl J Med 351, 2112-2114(2004) (Pubitemid 39482505)
163. R. Radi, M. Rodriguez, L. Castro and R. Telleri: Inhibition of mitochondrial electron transport by peroxynitrite. Arch Biochem Biophys 308, 89-95(1994) (Pubitemid 24172608)
164. S. B. Digerness, K. D. Harris, J. W. Kirklin, F. Urthaler, L. Viera, J. S. Beckman and V. Darley-Usmar: Peroxynitrite irreversibly decreases diastolic and systolic function in cardiac muscle. Free Radic Biol Med 27, 1386-1392(1999) (Pubitemid 30001501)
165. P. Pacher, J. S. Beckman and L. Liaudet: Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87, 315-424(2007) (Pubitemid 46217686)
166. J. N. Cohn, D. G. Archibald, S. Ziesche, J. A. Franciosa, W. E. Harston, F. E. Tristani, W. B. Dunkman, W. Jacobs, G. S. Francis, K. H. Flohr, S. Goldman, F. R. Cobb, P. M. Shah, R. Saunders, R. D. Fletcher, H. S. Loeb, V. C. Hughes and B. Baker: Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 314, 1547-1552(1986) (Pubitemid 16114684)
167. A. L. Taylor, S. Ziesche, C. Yancy, P. Carson, R. D'Agostino, Jr., K. Ferdinand, M. Taylor, K. Adams, M. Sabolinski, M. Worcel and J. N. Cohn: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351, 2049-2057(2004)
168. L. J. Ignarro, C. Napoli and J. Loscalzo: Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res 90, 21-28(2002) (Pubitemid 34074604)
169. T. Munzel, S. Kurz, S. Rajagopalan, M. Thoenes, W. R. Berrington, J. A. Thompson, B. A. Freeman and D. G. Harrison: Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest 98, 1465-1470(1996) (Pubitemid 26322073)
170. A. Daiber, M. Oelze, M. Coldewey, K. Kaiser, C. Huth, S. Schildknecht, M. Bachschmid, Y. Nazirisadeh, V. Ullrich, A. Mulsch, T. Munzel and N. Tsilimingas: Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. Biochem Biophys Res Commun 338, 1865-1874(2005) (Pubitemid 41643103)
171. B. Hornig, N. Arakawa, C. Kohler and H. Drexler: Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation 97, 363-368(1998) (Pubitemid 28074337)
172. S. H. Kubo, T. S. Rector, A. J. Bank, R. E. Williams and S. M. Heifetz: Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 84, 1589-1596(1991)
173. H. Drexler, D. Hayoz, T. Munzel, B. Hornig, H. Just, H. R. Brunner and R. Zelis: Endothelial function in chronic congestive heart failure. Am J Cardiol 69, 1596-1601(1992)
174. S. D. Katz, L. Biasucci, C. Sabba, J. A. Strom, G. Jondeau, M. Galvao, S. Solomon, S. D. Nikolic, R. Forman and T. H. LeJemtel: Impaired endothelium-mediated vasodilation in the peripheral vasculature of patients with congestive heart failure. J Am Coll Cardiol 19, 918-925(1992)
175. S. D. Katz, M. Schwarz, J. Yuen and T. H. LeJemtel: Impaired acetylcholine-mediated vasodilation in patients with congestive heart failure. Role of endothelium-derived vasodilating and vasoconstricting factors. Circulation 88, 55-61(1993) (Pubitemid 23195432)
176. A. Y. Chong, A. D. Blann, J. Patel, B. Freestone, E. Hughes and G. Y. Lip: Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation 110, 1794-1798(2004) (Pubitemid 39302656)
177. Y. Ishibashi, T. Shimada, T. Sakane, N. Takahashi, T. Sugamori, S. Ohhata, S. Inoue, H. Katoh, K. Sano, Y. Murakami and M. Hashimoto: Contribution of endogenous nitric oxide to basal vasomotor tone of peripheral vessels and plasma B-type natriuretic peptide levels in patients with congestive heart failure. J Am Coll Cardiol 36, 1605-1611(2000)
178. W. Doehner, N. Schoene, M. Rauchhaus, F. Leyva-Leon, D. V. Pavitt, D. A. Reaveley, G. Schuler, A. J. Coats, S. D. Anker and R. Hambrecht: Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 105, 2619-2624(2002) (Pubitemid 34596038)
179. C. A. Farquharson, R. Butler, A. Hill, J. J. Belch and A. D. Struthers: Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 106, 221-226(2002) (Pubitemid 34761303)
180. J. George, E. Carr, J. Davies, J. J. Belch and A. Struthers: High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 114, 2508-2516(2006) (Pubitemid 44901524)
181. F. A. Lopez and S. Casado: Heart failure, redox alterations, and endothelial dysfunction. Hypertension 38, 1400-1405(2001) (Pubitemid 34033423)
182. H. Drexler: Endothelium as a therapeutic target in heart failure. Circulation 98, 2652-2655(1998) (Pubitemid 28563997)
183. K. Tziomalos, V. G. Athyros, A. Karagiannis and D. P. Mikhailidis: Endothelial function, arterial stiffness and lipid lowering drugs. Expert Opin Ther Targets 11, 1143-1160(2007) (Pubitemid 47532862)
184. K. Arimura, K. Egashira, R. Nakamura, T. Ide, H. Tsutsui, H. Shimokawa and A. Takeshita: Increased inactivation of nitric oxide is involved in coronary endothelial dysfunction in heart failure. Am J Physiol Heart Circ Physiol 280, H68-H75 (2001)
185. A. F. van den Heuvel, D. J. van Veldhuisen, E. E. van der Wall, P. K. Blanksma, H. M. Siebelink, W. M. Vaalburg, W. H. van Gilst and H. J. Crijns: Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 35, 19-28(2000) (Pubitemid 30061254)
186. S. D. Katz, K. Hryniewicz, I. Hriljac, K. Balidemaj, C. Dimayuga, A. Hudaihed and A. Yasskiy: Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 111, 310-314(2005) (Pubitemid 40165337)
187. T. Heitzer, S. Baldus, Y. von Kodolitsch, V. Rudolph and T. Meinertz: Systemic endothelial dysfunction as an early predictor of adverse outcome in heart failure. Arterioscler Thromb Vasc Biol 25, 1174-1179(2005) (Pubitemid 40776605)
188. D. Fischer, S. Rossa, U. Landmesser, S. Spiekermann, N. Engberding, B. Hornig and H. Drexler: Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J 26, 65-69(2005) (Pubitemid 40221125)
189. W. S. Waring, D. J. Webb and S. R. Maxwell: Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol 38, 365-371(2001) (Pubitemid 32769556)
190. H. U. Hink, N. Santanam, S. Dikalov, L. McCann, A. D. Nguyen, S. Parthasarathy, D. G. Harrison and T. Fukai: Peroxidase properties of extracellular superoxide dismutase: role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol 22, 1402-1408(2002)
191. R. J. Johnson, D. H. Kang, D. Feig, S. Kivlighn, J. Kanellis, S. Watanabe, K. R. Tuttle, B. Rodriguez-Iturbe, J. Herrera-Acosta and M. Mazzali: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41, 1183-1190(2003) (Pubitemid 36706063)
192. B. N. Ames, R. Cathcart, E. Schwiers and P. Hochstein: Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 78, 6858-6862(1981) (Pubitemid 12216861)
193. M. G. Netea, B. J. Kullberg, W. L. Blok, R. T. Netea and J. W. van der Meer: The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice. Blood 89, 577-582(1997) (Pubitemid 27051694)
194. J. Kanellis, S. Watanabe, J. H. Li, D. H. Kang, P. Li, T. Nakagawa, A. Wamsley, D. Sheikh-Hamad, H. Y. Lan, L. Feng and R. J. Johnson: Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 41, 1287-1293(2003) (Pubitemid 36706079)
195. D. H. Kang, S. K. Park, I. K. Lee and R. J. Johnson: Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 16, 3553-3562(2005) (Pubitemid 46211276)
196. M. H. Ginsberg, F. Kozin, M. O'Malley and D. J. McCarty: Release of platelet constituents by monosodium urate crystals. J Clin Invest 60, 999-1007(1977) (Pubitemid 8223125)
197. D. H. Kang, L. Han, X. Ouyang, A. M. Kahn, J. Kanellis, P. Li, L. Feng, T. Nakagawa, S. Watanabe, M. Hosoyamada, H. Endou, M. Lipkowitz, R. Abramson, W. Mu and R. J. Johnson: Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol 25, 425-433(2005) (Pubitemid 41433885)
198. G. N. Rao, M. A. Corson and B. C. Berk: Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 266, 8604-8608(1991) (Pubitemid 21906552)
199. W. S. Waring, D. J. Webb and S. R. Maxwell: Uric acid as a risk factor for cardiovascular disease. QJM 93, 707-713(2000)
200. M. J. Bos, P. J. Koudstaal, A. Hofman, J. C. Witteman and M. M. Breteler: Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 37, 1503-1507(2006) (Pubitemid 44305733)
201. J. Fang and M. H. Alderman: Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 283, 2404-2410(2000) (Pubitemid 30257539)
202. L. K. Niskanen, D. E. Laaksonen, K. Nyyssonen, G. Alfthan, H. M. Lakka, T. A. Lakka and J. T. Salonen: Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 164, 1546-1551(2004) (Pubitemid 38970476)
203. V. G. Athyros, M. Elisaf, A. A. Papageorgiou, A. N. Symeonidis, A. N. Pehlivanidis, V. I. Bouloukos, H. J. Milionis and D. P. Mikhailidis: Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 43, 589-599(2004) (Pubitemid 38401873)
204. V. G. Athyros, D. P. Mikhailidis, E. N. Liberopoulos, A. I. Kakafika, A. Karagiannis, A. A. Papageorgiou, K. Tziomalos, E. S. Ganotakis and M. Elisaf: Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 22, 118-127(2007) (Pubitemid 46050336)
205. A. Karagiannis, D. P. Mikhailidis, K. Tziomalos, M. Sileli, S. Savvatianos, A. Kakafika, T. Gossios, N. Krikis, I. Moschou, M. Xochellis and V. G. Athyros: Serum uric acid as an independent predictor of early death after acute stroke. Circ J 71, 1120-1127(2007) (Pubitemid 46998030)
206. F. Leyva, S. Anker, J. W. Swan, I. F. Godsland, C. S. Wingrove, T. P. Chua, J. C. Stevenson and A. J. Coats: Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 18, 858-865(1997) (Pubitemid 27208159)
207. F. Leyva, S. D. Anker, I. F. Godsland, M. Teixeira, P. G. Hellewell, W. J. Kox, P. A. Poole-Wilson and A. J. Coats: Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 19, 1814-1822(1998) (Pubitemid 28556651)
208. M. M. Kittleson, M. E. St John, V. Bead, H. C. Champion, E. K. Kasper, S. D. Russell, I. S. Wittstein and J. M. Hare: Increased levels of uric acid predict haemodynamic compromise in patients with heart failure independently of B-type natriuretic peptide levels. Heart 93, 365-367(2007) (Pubitemid 46579533)
209. J. M. Hare and R. J. Johnson, Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation 107, 1951-1953(2003) (Pubitemid 36506064)
210. W. Doehner, M. Rauchhaus, V. G. Florea, R. Sharma, A. P. Bolger, C. H. Davos, A. J. Coats and S. D. Anker: Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance. Am Heart J 141, 792-799(2001) (Pubitemid 32378489)
211. S. D. Anker, F. Leyva, P. A. Poole-Wilson, W. J. Kox, J. C. Stevenson and A. J. Coats: Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure. Heart 78, 39-43(1997) (Pubitemid 27346879)
212. M. Cicoira, L. Zanolla, A. Rossi, G. Golia, L. Franceschini, G. Brighetti, P. Zeni and P. Zardini: Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy. Am Heart J 143, 1107-1111(2002) (Pubitemid 34666905)
213. S. D. Anker, W. Doehner, M. Rauchhaus, R. Sharma, D. Francis, C. Knosalla, C. H. Davos, M. Cicoira, W. Shamim, M. Kemp, R. Segal, K. J. Osterziel, F. Leyva, R. Hetzer, P. Ponikowski and A. J. Coats: Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 107, 1991-1997(2003) (Pubitemid 36506072)
214. H. Sakai, T. Tsutamoto, T. Tsutsui, T. Tanaka, C. Ishikawa and M. Horie: Serum level of uric acid, partly secreted from the failing heart, is a prognostic marker in patients with congestive heart failure. Circ J 70, 1006-1011(2006) (Pubitemid 44161737)
215. E. A. Jankowska, B. Ponikowska, J. Majda, R. Zymlinski, M. Trzaska, K. Reczuch, L. Borodulin-Nadzieja, W. Banasiak and P. Ponikowski: Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure. Int J Cardiol 115, 151-155(2007) (Pubitemid 46136516)
216. M. M. Kittleson, V. Bead, M. Fradley, M. E. St John, H. C. Champion, E. K. Kasper, S. D. Russell, I. S. Wittstein and J. M. Hare: Elevated uric acid levels predict allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transplant 26, 498-503(2007) (Pubitemid 46602011)
217. A. Hoieggen, M. H. Alderman, S. E. Kjeldsen, S. Julius, R. B. Devereux, U. De Faire, F. Fyhrquist, H. Ibsen, K. Kristianson, O. Lederballe-Pedersen, L. H. Lindholm, M. S. Nieminen, P. Omvik, S. Oparil, H. Wedel, C. Chen and B. Dahlof: The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 65, 1041-1049(2004) (Pubitemid 38251080)
218. K. J. Cheung, I. Tzameli, P. Pissios, I. Rovira, O. Gavrilova, T. Ohtsubo, Z. Chen, T. Finkel, J. S. Flier and J. M. Friedman: Xanthine oxidoreductase is a regulator of adipogenesis and PPARgamma activity. Cell Metab 5, 115-128(2007) (Pubitemid 46187493)
219. R. M. Evans, G. D. Barish and Y. X. Wang: PPARs and the complex journey to obesity. Nat Med 10, 355-361(2004) (Pubitemid 38508511)
220. T. Ohtsubo, I. I. Rovira, M. F. Starost, C. Liu and T. Finkel: Xanthine oxidoreductase is an endogenous regulator of cyclooxygenase-2. Circ Res 95, 1118-1124(2004) (Pubitemid 39557899)
221. K. Kalantar-Zadeh, G. Block, T. Horwich and G. C. Fonarow: Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 43, 1439-1444(2004) (Pubitemid 38496352)
222. A. Yndestad, J. K. Damas, E. Oie, T. Ueland, L. Gullestad and P. Aukrust: Systemic inflammation in heart failure-the whys and wherefores. Heart Fail Rev 11, 83-92(2006) (Pubitemid 43986210)
223. S. Baldus, K. Mullerleile, P. Chumley, D. Steven, V. Rudolph, G. K. Lund, H. J. Staude, A. Stork, R. Koster, J. Kahler, C. Weiss, T. Munzel, T. Meinertz, B. A. Freeman and T. Heitzer: Inhibition of xanthine oxidase improves myocardial contractility in patients with ischemic cardiomyopathy. Free Radic Biol Med 41, 1282-1288(2006) (Pubitemid 44466324)
224. A. D. Gavin and A. D. Struthers: Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart 91, 749-753(2005) (Pubitemid 40769216)
225. R. Latini, S. Masson, I. Anand, M. Salio, A. Hester, D. Judd, S. Barlera, A. P. Maggioni, G. Tognoni and J. N. Cohn: The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 25, 292-299(2004) (Pubitemid 38295437)
226. B. Stanek, B. Frey, M. Hulsmann, R. Berger, B. Sturm, J. Strametz-Juranek, J. Bergler-Klein, P. Moser, A. Bojic, E. Hartter and R. Pacher: Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 38, 436-442(2001) (Pubitemid 32721772)
227. H. E. Cingolani, J. A. Plastino, E. M. Escudero, B. Mangal, J. Brown and N. G. Perez: The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study. J Card Fail 12, 491-498(2006) (Pubitemid 44307706)
228. R. S. Freudenberger, R. P. Schwarz, Jr., J. Brown, A. Moore, D. Mann, M. M. Givertz, W. S. Colucci and J. M. Hare: Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class. Expert Opin Investig Drugs 13, 1509-1516(2004) (Pubitemid 39530203)
229. J. M. Hare, B. Mangal, J. Brown, C. Fisher, R. S. Freudenberger, W. S. Colucci, D. L. Mann, P. Liu, M. M. Givertz and R. P. Schwarz: Impact of Oxypurinol in Patients with Symptomatic Heart failure: Results of the OPT-CHF Study. J Am Coll Cardiol (2008) In press.
230. P. Pacher, A. Nivorozhkin and C. Szabo: Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 58, 87-114(2006)
231. P. C. Moorhouse, M. Grootveld, B. Halliwell, J. G. Quinlan and J. M. Gutteridge: Allopurinol and oxypurinol are hydroxyl radical scavengers. FEBS Lett 213, 23-28(1987) (Pubitemid 17036125)
232. E. E. Kelley, A. Trostchansky, H. Rubbo, B. A. Freeman, R. Radi and M. M. Tarpey: Binding of xanthine oxidase to glycosaminoglycans limits inhibition by oxypurinol. J Biol Chem 279, 37231-37234(2004) (Pubitemid 39195428)